Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HX008 plus capecitabine and oxaliplatin in advanced gastric cancer
CTR20181270Phase 2Completed
- Sponsor
- Taizhou Hanzhong Biomedical
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of pucotenlimab in gastric cancer (GC), esophagogastric junction cancer, sponsored by Taizhou Hanzhong Biomedical. Started Aug 2018; status: completed.
02
Drugs
pucotenlimab
03
Conditions
gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on CTR20181270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181270.